Managing the skin toxicities from new melanoma drugs.
Patients treated with ipilimumab or targeted inhibitors of the RAF-MEK-ERK pathway (vemurafenib, dabrafenib, and trametinib) for advanced cutaneous melanoma often experience drug-related skin toxicities denoted as dermatologic adverse events (DAEs). Although rarely life-threatening, DAEs may emerge...
| Publicado en: | Current Treatment Options in Oncology Vol. 15; no. 2; pp. 281 - 302 |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Jun2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103827309&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 103827309 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Jun2014 vid: 15 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 103827309 96329616 NLM24867225 2012607229 10.1007/s11864-014-0284-6 NLM24867225 103827309 ppf: 281 ppct: 21 formats: fmt: @attributes: type: P tig: atl: Managing the skin toxicities from new melanoma drugs. aug: au: Mavropoulos, John C Wang, Timothy S affil: Department of Dermatology, Johns Hopkins Outpatient Center, Johns Hopkins University, 601 N. Caroline Street, Baltimore, MD, 21287, USA, drjohnmavpub@gmail.com. sug: subj: Antineoplastic Agents Adverse Effects Melanoma Drug Therapy Skin Drug Effects Skin Neoplasms Drug Therapy Antibodies, Monoclonal Adverse Effects Imidazoles Adverse Effects Indoles Adverse Effects Inflammation Amines Adverse Effects Pyridines Adverse Effects Heterocyclic Compounds Adverse Effects Dermatitis Medicamentosa Sulfonamides Adverse Effects Treatment Outcomes ab: Patients treated with ipilimumab or targeted inhibitors of the RAF-MEK-ERK pathway (vemurafenib, dabrafenib, and trametinib) for advanced cutaneous melanoma often experience drug-related skin toxicities denoted as dermatologic adverse events (DAEs). Although rarely life-threatening, DAEs may emerge dramatically and potentially compromise oncologic therapy if not managed in a timely and effective manner. Early recognition of DAEs is critical to providing optimal skin care and prompt consultation with a dermatologist should be obtained when a diagnosis is unclear. The expanding utilization of new melanoma drugs compels physicians to maintain a watchful eye for both known and novel DAEs and to adopt a low threshold to biopsy worrisome skin findings. Numerous therapeutic options are available to manage DAEs including topical and systemic agents as well as surgical and destructive modalities. Applying such methods improves overall patient care and optimizes the effectiveness of new therapies for advanced cutaneous melanoma. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|